The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | RELEVANCE trial analysis: investigating the impact of lymphocyte/monocyte ratio on patient outcomes
Pablo Mozas, MD, PhD, Hospital Clinic Barcelona, Barcelona, Spain, discusses the impact of the tumor microenvironment in follicular lymphoma (FL), highlighting the importance of analyzing the lymphocyte-to-monocyte ratio in this disease. Dr Mozas then summarizes the findings from an analysis of the RELEVANCE trial (NCT01650701) which investigated whether the lymphocyte-to-monocyte ratio had an impact on the survival of patients enrolled in this trial. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
